A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer
Latest Information Update: 19 Dec 2024
At a glance
- Drugs MBQ-167 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; First in man
- Sponsors MBQ Pharma
Most Recent Events
- 12 Dec 2024 Planned End Date changed from 31 Oct 2024 to 31 Oct 2025.
- 12 Dec 2024 Planned primary completion date changed from 1 Oct 2024 to 1 Oct 2025.
- 12 Oct 2023 New trial record